Our pipeline includes early- to late-stage investigational candidates that address the cognitive, functional and behavioral needs of patients with Alzheimer's disease and other forms of dementia.
Intepirdine, our lead investigational candidate, is a 5HT6 receptor antagonist in Phase 3 development for the treatment of Alzheimer's disease and dementia with Lewy bodies (DLB). In Alzheimer's disease, intepirdine is being developed as an adjunct therapy to the generic cholinesterase inhibitor donepezil.
Nelotanserin, our second investigational candidate, is a potent and highly selective 5HT2A receptor inverse agonist being evaluated for safety and efficacy in Phase 2 development for three indications: visual hallucinations in patients with DLB; REM sleep behavior disorder (RBD) in patients with DLB; and Parkinson’s disease dementia (PDD).
RVT-103 and RVT-104 are in early-stage development as approaches to improve the tolerability and reduce the gastrointestinal side effects associated with cholinesterase inhibitors for the treatment of dementia.
5HT6 Receptor Antagonist
Mild-to-Moderate Alzheimer’s Disease
Dementia with Lewy Bodies (DLB)
Gait and Balance Impairments in Dementia
5HT2A Receptor Inverse Agonist
Visual Hallucinations in Lewy Body Dementia
REM Sleep Behavior Disorder (RBD) in Lewy Body Dementia
RVT-103 & RVT-104
QAAM + Cholinesterase Inhibitor Combination
Lewy Body Dementia
Axovant owns worldwide rights to all of our product candidates in development today.
These are investigational new drug candidates and are not approved for any indication in any markets.